AlloMap Molecular Expression Testing

New from XDx – Announcing…

AlloMap molecular expression testing is now available for cardiac transplants as early as 2 months post cardiac transplant!

For cardiac transplant patients, acute cellular rejection is most worrisome in the first months post transplant. As of Monday, August 21, 2006, AlloMap molecular expression testing is available to help you monitor patients as early as 2 months post cardiac transplant. When combined with patient assessment, AlloMap testing can provide the confidence you need to rule out acute cellular rejection.

Freedom from Future Rejection

A CARGO sub-study showed that patients with scores < 20 in the first 6 months post transplant were free from ACR ≥ 3A(2R) for the next 80 days (~12 weeks)¹.

¹ Data on File

Transplant Clinic

Patients & Families

Lab Professionals

Discover XDx

Transplant Clinic

Font Size:

	AlloMap Testing Description
	Developing AlloMap Testing
	Billing & Reimbursement

Existing customers: click here to order supplies.

Billing and Reimbursement

XDx Typically Bills Insurers Directly for AlloMap Testing

Consistent with the established billing practice for specialized esoteric tests, XDx can bill the patient's health insurer directly. In these cases, medical institutions that order AlloMap testing will not be financially responsible for the test.¹

AlloMap testing is priced below the average reimbursement rates for endomyocardial biopsy.² Even more importantly, AlloMap testing can offer a clinical advancement to the physician and patient, as well as an economical solution for the health care system.

Insurers are reimbursing for AlloMap testing ordered for their members.

Working Together to Educate Insurers Not Yet Covering AlloMap Testing

XDx is committed to working with transplant clinics and patients to ensure that AlloMap tests receive appropriate consideration from the patient’s insurer. Cooperation from both clinician and patient is sometimes necessary for XDx to secure coverage from the insurer for the AlloMap test.

XDx shares the concerns of the transplant team in placing an additional financial burden on the patient. As a result, XDx created a patient advocacy and financial assistance program that assists both uninsured and underinsured patients for whom AlloMap testing is ordered. This program assists patients in obtaining the best coverage/reimbursement for this test from their insurers. Additionally, as part of this program, XDx gives preferred pricing for the test to payers who remove co-pay or co-insurance requirements for the test.

Get Answers to Your Questions and Concerns

Contact your local XDx Reimbursement or Transplant Account Manager or call 1-888-ALLOMAP (1-888-255-6627) Monday to Friday from 6 AM to 5 PM (Pacific Time) to learn about coverage policies and financial assistance programs for AlloMap molecular expression testing.

XDx bills the medical center only under the following circumstances: a) when tests are ordered within the case rate period (agreed upon between the health plan and the medical center); b) when tests are ordered for an inpatient with Medicare coverage; c) when the medical center policy is to bill insurers directly for all tests; and d) when the medical facility providing service is also the insurer.

Evans RW, Williams GE, Baron HM, Deng MC, Eisen HJ, Hunt SA, et al. The Economic Implications of Molecular Testing in Cardiac Transplantation: Endomyocardial Biopsy Costs, Reimbursement and Financial Impact of Noninvasive Management Strategies. J Heart Lung Transplant 2005.